Chess; Leonard

Patent Applications and Registrations

Patent applications and USPTO patent grants for Chess; Leonard.The latest application filed is for "methods to activate or block the hla-e/qa-1 restricted cd8+ t cell regulatory pathway to treat immunological disease".

Company Profile

1.14.16

Chess; Leonard - Scarsdale NY

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Methods to activate or block the HLA-E/Qa-1 restricted CD8+ T cell regulatory pathway to treat immunological disease App 20190389953 - Jiang; Hong ; et al.	2019-12-26
Methods of preventing rejection of transplanted tissue by administering anti-CD40L antibody and HLA-E-bearing composition Grant 9,597,381 - Jiang , et al. March 21, 2	2017-03-21
Methods to activate or block the HLA-E/Qa-1 restricted CD8+ T cell regulatory pathway to treat immunological disease App 20170058034 - Jiang; Hong ; et al.	2017-03-02
Methods to activate or block the HLA-E/Qa-1 restricted CD8+ T cell regulatory pathway to treat immunological disease Grant 9,421,249 - Jiang , et al. August 23, 2	2016-08-23
Methods of Preventing Rejection of Transplanted Tissue by Administering Anti-CD40L Antibody and Dendritic Cells Loaded with Type B Peptide App 20160095909 - Jiang; Hong ; et al.	2016-04-07
Methods of preventing rejection of transplanted tissue by administering anti-CD40L antibody and dendritic cells loaded with type B peptide Grant 9,155,787 - Jiang , et al. October 13, 2	2015-10-13
Methods of Establishing Long-Term Donor-specific Transplantation Tolerance App 20150110813 - Jiang; Hong ; et al.	2015-04-23
Methods of preventing rejection of transplanted tissue by administering anti-CD40L antibody and dendritic cells loaded with Hsp60sp peptide Grant 8,911,739 - Jiang , et al. December 16, 2	2014-12-16
Methods to activate or block the HLA-E/Qa-1 restricted CD8+ T cell regulatory pathway to treat immunological disease App 20130209498 - Jiang; Hong ; et al.	2013-08-15
Assay For Determining Health Of Cd8+ T Cells App 20120183518 - Jiang; Hong ; et al.	2012-07-19
Use Of 5c8 Mab And Direct Induction Of Regulatory Cd8+ T Cells To Establish Permanent And Specific Transplantation Tolerance App 20120029473 - Jiang; Hong ; et al.	2012-02-02
Methods to activate or block the HLA-E/Qa-1 restricted CD8+ T cell regulatory pathway to treat immunological disease App 20100267622 - Jiang; Hong ; et al.	2010-10-21
Therapeutic applications of T-BAM (CD40L) technology to treat diseases involving smooth muscle cells App 20080050369 - Yellin; Michael J. ; et al.	2008-02-28
Method for inhibiting inflammation with an antibody that binds the 5C8 protein Grant 7,070,777 - Lederman , et al. July 4, 2	2006-07-04
Murine monoclonal antibody (5c8) recognizes T-B cell activating molecule (T-BAM) (CD40 LIGAND) on the surface of T-lymphocytes, compositions containing same and methods of use App 20060110392 - Lederman; Seth ; et al.	2006-05-25
Therapeutic applications for the anti-T-BAM (CD40-1) monoclonal antibody 5C8 App 20050118166 - Yellin, Michael J. ; et al.	2005-06-02
5c8 Antigen App 20050037005 - Lederman, Seth ; et al.	2005-02-17
Protein recognized by an antibody that specifically binds an epitope that is specifically bound by monoclonal antibody 5c8. Grant 6,793,924 - Lederman , et al. September 21, 2	2004-09-21
Therapeutic applications of T-BAM (CD40L) technology to treat diseases involving smooth muscle cells App 20030219437 - Yellin, Michael J. ; et al.	2003-11-27
Methods of inhibiting an autoimmune response in a human suffering from an autoimmune disease by administering an antibody that binds to a protein to which monoclonal antibody 5C8 binds Grant 6,610,294 - Lederman , et al. August 26, 2	2003-08-26
Regulation Of Activated T Cells By Recognition Of T Cell Receptor Beta Chains And Major Histocompatibility Complex Class Ib Molecules App 20030103988 - CHESS, LEONARD ; et al.	2003-06-05
Therapeutic Applications For The Anti-t-bam (cd40l) Monoclonal Antibody 5c8 In The Treatment Of Vasculitis App 20030099642 - YELLIN, MICHAEL J. ; et al.	2003-05-29
5c8 Antigen App 20030077280 - Lederman, Seth ; et al.	2003-04-24
DNA encoding the T cell surface protein T4 and use of fragments of T4 in the treatment of AIDS Grant 6,093,539 - Maddon , et al. July 25, 2	2000-07-25
DNA encoding the T cell surface protein T4 and use of fragments of T4 in the treatment of AIDS Grant 5,958,678 - Maddon , et al. September 28, 1	1999-09-28
Antibody which is directed against and inhibits collagen binding to a VLA-1 epitope and uses thereof Grant 5,788,966 - Chess , et al. August 4, 1	1998-08-04
Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same Grant 5,474,771 - Lederman , et al. December 12, 1	1995-12-12
Antibody which is directed against and inhibits collagen binding to a VLA-1 epitope and uses thereof Grant 5,391,481 - Chess , et al. February 21, 1	1995-02-21
Soluble forms of the T cell surface protein CD4 Grant 5,126,433 - Maddon , et al. June 30, 1	1992-06-30

Company Registrations

NCAGE Code	48QW3	CHESS LEONARD
CAGE Code	48QW3	CHESS, LEONARD

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.